Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Journal of Oncology|December 31, 2020
Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor TherapyNora Möhn, Susann Mahjoub, Ralf Gutzmer, et al.
Future Oncology (London, England)|May 19, 2025
Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in ItalyPhilipp Ivanyi, Ash Bullement, Andrea Botticelli, et al.
BMC Genomics|October 21, 2006
Identification of novel regulators in T-cell differentiation of aplastic anemia patientsAnke Franzke, Robert Geffers, J Katrin Hunger, et al.
Scientific Reports|February 12, 2019
Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patientsChristine G Stöhr, Sandra Steffens, Iris Polifka, et al.
Cancer Treatment Reviews|March 11, 2025
Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neckPetr Szturz, Thorsten Fuereder, Ye Guo, et al.
Immunological Investigations|October 23, 2012
Reconstitution and phenotype of Tregs in CMV reactivating patients following allogeneic hematopoietic stem cell transplantationSarvari Velaga, Sya N Ukena, Matthias Höpting, et al.
Scientific Reports|July 30, 2025
Impact of local therapy in metastatic renal cell carcinoma during medical treatment in a retrospective analysisSena Hoffer, Hendrik Eggers, Tabea Fröhlich, et al.
Computerized Medical Imaging and Graphics : the Official Journal of the Computerized Medical Imaging Society|May 19, 2023
Valuing vicinity: Memory attention framework for context-based semantic segmentation in histopathologyOliver Ester, Fabian Hörst, Constantin Seibold, et al.
Oncology Research and Treatment|December 22, 2025
Frontline pembrolizumab or methotrexate in elderly, frail, or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) - results of the randomized phase 2 study ELDORANDO (AIO-KHT-0115)Konrad Klinghammer, Ullrich Graeven, Philipp Ivanyi, et al.
British Journal of Cancer|July 18, 2026
OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)Viktor Grünwald, Jürgen Alt, Mareike Tometten, et al.
Pageof 10